Literature DB >> 28128692

Volume-staged versus dose-staged stereotactic radiosurgery outcomes for large brain arteriovenous malformations: a systematic review.

Adeel Ilyas1, Ching-Jen Chen1, Dale Ding1, Davis G Taylor1, Shayan Moosa1, Cheng-Chia Lee2, Or Cohen-Inbar1, Jason P Sheehan1.   

Abstract

OBJECTIVE Several recent studies have improved our understanding of the outcomes of volume-staged (VS) and dose-staged (DS) stereotactic radiosurgery (SRS) for the treatment of large (volume > 10 cm3) brain arteriovenous malformations (AVMs). In light of these recent additions to the literature, the aim of this systematic review is to provide an updated comparison of VS-SRS and DS-SRS for large AVMs. METHODS A systematic review of the literature was performed using PubMed to identify cohorts of 5 or more patients with large AVMs who had been treated with VS-SRS or DS-SRS. Baseline data and post-SRS outcomes were extracted for analysis. RESULTS A total of 11 VS-SRS and 10 DS-SRS studies comprising 299 and 219 eligible patients, respectively, were included for analysis. The mean obliteration rates for VS-SRS and DS-SRS were 41.2% (95% CI 31.4%-50.9%) and 32.3% (95% CI 15.9%-48.8%), respectively. Based on pooled individual patient data, the outcomes for patients treated with VS-SRS were obliteration in 40.3% (110/273), symptomatic radiation-induced changes (RICs) in 13.7% (44/322), post-SRS hemorrhage in 19.5% (50/256), and death in 7.4% (24/323); whereas the outcomes for patients treated with DS-SRS were obliteration in 32.7% (72/220), symptomatic RICs in 12.2% (31/254), post-SRS hemorrhage in 10.6% (30/282), and death in 4.6% (13/281). CONCLUSIONS Volume-staged SRS appears to afford higher obliteration rates than those achieved with DS-SRS, although with a less favorable complication profile. Therefore, VS-SRS or DS-SRS may be a reasonable treatment approach for large AVMs, either as stand-alone therapy or as a component of a multimodality management strategy.

Entities:  

Keywords:  AVM = arteriovenous malformation; DS-SRS = dose-staged SRS; GK = Gamma Knife; Gamma Knife; LINAC = linear accelerator; RIC = radiation-induced change; SRS = stereotactic radiosurgery; SS-SRS = single-session SRS; VS-SRS = volume-staged SRS; arteriovenous malformation; dose-staged; radiosurgery; review; stereotactic radiosurgery; vascular disorders; volume-staged

Mesh:

Year:  2017        PMID: 28128692     DOI: 10.3171/2016.9.JNS161571

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  Surgical Approaches for Symptomatic Cerebral Cavernous Malformations of the Thalamus and Brainstem.

Authors:  Dale Ding; Robert M Starke; R Webster Crowley; Kenneth C Liu
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2017-03-31

2.  Extensive Cerebral Arteriovenous Malformation-Associated Intraventricular Hemorrhage.

Authors:  Amine Awad; Kow Essuman; Robert W Regenhardt; Thabele M Leslie-Mazwi; Aman B Patel; Christopher J Stapleton
Journal:  Neurohospitalist       Date:  2021-09-27

3.  Stereotactic radiosurgery with versus without prior Onyx embolization for brain arteriovenous malformations.

Authors:  Ching-Jen Chen; Dale Ding; Cheng-Chia Lee; Kathryn N Kearns; I Jonathan Pomeraniec; Christopher P Cifarelli; David E Arsanious; Roman Liscak; Jaromir Hanuska; Brian J Williams; Mehran B Yusuf; Shiao Y Woo; Natasha Ironside; Rebecca M Burke; Ronald E Warnick; Daniel M Trifiletti; David Mathieu; Monica Mureb; Carolina Benjamin; Douglas Kondziolka; Caleb E Feliciano; Rafael Rodriguez-Mercado; Kevin M Cockroft; Scott Simon; Heath B Mackley; Samer G Zammar; Neel T Patel; Varun Padmanaban; Nathan Beatson; Anissa Saylany; John Y K Lee; Jason P Sheehan
Journal:  J Neurosurg       Date:  2020-12-11       Impact factor: 5.408

4.  Factors Affecting Volume Reduction Velocity for Arteriovenous Malformations After Treatment With Dose-Stage Stereotactic Radiosurgery.

Authors:  Xiangyu Meng; Dezhi Gao; Hengwei Jin; Kuanyu Wang; Enmeng Bao; Ali Liu; Youxiang Li; Shibin Sun
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

5.  The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers.

Authors:  Xuexue Bai; Meng Zhou
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

6.  Intermixed arteriovenous malformation and hemangioblastoma: case report and literature review.

Authors:  Vincent Healy; Philip J O'Halloran; Mohammed B Husien; Ciaran Bolger; Michael Farrell
Journal:  CNS Oncol       Date:  2020-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.